

LB/TH/28/2026

TH6271

**DEVELOPMENT OF A SYSTEM TO ANALYZE
PHYSIOLOGICAL PARAMETERS THAT ARE
INFLUENCED BY ENDOTHELIAL
DYSFUNCTION TO ASSESS RISKS OF DIABETES**

KG Samarawickrama

188024N

Master of Philosophy

Department of Electronic and Telecommunication Engineering
Faculty of Engineering

University of Moratuwa
Sri Lanka

April 2026

**DEVELOPMENT OF A SYSTEM TO ANALYZE
PHYSIOLOGICAL PARAMETERS THAT ARE
INFLUENCED BY ENDOTHELIAL
DYSFUNCTION TO ASSESS RISKS OF DIABETES**

KG Samarawickrama

188024N

Thesis submitted in partial fulfillment of the requirements for the degree
Master of Philosophy

Department of Electronic and Telecommunication Engineering
Faculty of Engineering

University of Moratuwa
Sri Lanka

April 2026

DECLARATION

I declare that this is my own work and this Thesis does not incorporate without acknowledgement any material previously submitted for a Degree or Diploma in any other University or Institute of higher learning and to the best of my knowledge and belief it does not contain any material previously published or written by another person except where the acknowledgement is made in the text. I retain the right to use this content in whole or part in future works (such as articles or books).

Signature:

Date: 23/04/2026

The supervisors should certify the Thesis with the following declaration.

The above candidate has carried out research for the Master of Philosophy Thesis under our supervision. We confirm that the declaration made above by the student is true and correct.

Name of Supervisor: Dr. MR Liyanaarachchi

Signature of the Supervisor:

Date: 24/04/2026

Name of Supervisor: Dr. AC De Silva

Signature of the Supervisor:

Date: 24/04/2026

Name of Supervisor: Prof. S Jayasinghe

Signature of the Supervisor:

Date: 24/04/2026

ACKNOWLEDGEMENT

I would like to extend my gratitude to my supervisors, Dr. Rukshani Liyanaarachchi and Dr. Anjula De Silva and Department of Electronic and Telecommunication Engineering, Faculty of Engineering, University of Moratuwa and Prof. Saroj Jayasinghe, Department of Clinical Medicine, Faculty of Medicine, University of Colombo for their academic advice, continuous guidance and the tremendous support given to me throughout my research study. Special thank goes to Mr. Nipun Dileesha Perera for the support given to me at the initiation of the research project.

Furthermore, I would like to thank the Department of Electronic and Telecommunication Engineering, Faculty of Engineering, University of Moratuwa for facilitating the infrastructure and laboratories to conduct my MPhil degree.

Special thank goes to Prof. Mandika Wijerathne, Prof. Saroj Jayasinghe and Mrs. Tharanga for granting permission to access National Hospital -Sri Lanka (NHSL) premises to perform the preliminary data collection.

Special thank goes to Prof. Ranil Jayawardene and Health and Wellness unit, Faculty of Medicine, University of Colombo, for facilitating the laboratory premises for experimental data collections for device validation.

Additionally, I would like to convey my sincere gratitude to Dr. Mahen Wijesuriya, Mrs. Dhanya Wijesuriya, Mrs. Thamilini Joseph, Dr. Kasun Perera and Dr. Darshika Ariyasena of Diabetes Association of Sri Lanka for providing centre premises to conduct the clinical study data collection.

ABSTRACT

Vasodilatory Endothelial Dysfunction (VED) is identified as a precursor to cardiovascular diseases (CVDs) and atherosclerosis. Therefore, early detection of VED is important to prevent the development of severe CVDs and prescribe lifestyle changes or make clinical interventions. Though coronary angiography is the gold standard to detect VED, specialized devices have provided alternative means of detecting VED non-invasively. With these, they have detected VED in patients who are already diagnosed with CVD or Diabetes Mellitus (DM). Here, we investigated early detection of VED under four subject categories: individuals with pre-diabetes (PDM); healthy individuals with CVD risk factors (HRF); individuals with DM; and individuals with CVD. Non-invasively measured physiological parameters were used to detect VED. We developed a custom-made device to record non-invasive physiological parameters from the distal end of upper limbs namely, Digital Body Temperature, Peripheral Arterial Tone, Photo Plethysmography and Peripheral Bio-impedance. Multiple indices which represent unique features of these parameters were calculated considering both long-term and short-term variations. Using these, the performance of this device was validated against the flow-mediated dilation (FMD) procedure in a preliminary study with 10 volunteers (age range: 35 - 60 years): 5 healthy subjects (control) and 5 CVD patients with/without DM. Then the clinical study was conducted with 69 participants (age range: 35-60 years) with all the subject categories: healthy (n=9), HRF (n=15), PDM (n=6), type 2 DM (n=15), CVD with/without DM (n=24). CVD risk factors identified for the HRF category were physical inactivity, unhealthy diet, smoking, alcohol consumption, body mass index, and family history of CVD. Participants with type-1 DM, liver cirrhosis, renal failure, thyroid disease, spinal cord injuries, and finger deformities were excluded from the study. In the preliminary study, an unpaired t-test performed between FMD readings and indices derived from parameters calculated from the custom-made device validated device performance. In the clinical study, the ANOVA analysis showed promising results ($p < 0.05$) in distinguishing long-term trend variations and short-term variations of VED-associated physiological parameters in test subjects diagnosed with CVD or DM along with preclinical stages compared to the healthy conditions. Thereby, we have demonstrated that it may be possible to detect the early development of CVD in preclinical stages through monitoring these VED-associated physiological parameters.

Keywords: Vasodilatory Endothelial Dysfunction, Cardiovascular diseases, Risk factors, Pre-Diabetes, Peripheral Bio-impedance

TABLE OF CONTENTS

Declaration of the Candidate & Supervisor	i
Acknowledgement	ii
Abstract	iii
Table of Contents	iv
List of Figures	viii
List of Tables	xiv
List of Appendices	xvi
1 Introduction	1
1.1 Outline of the Thesis	4
2 Literature Review and Research Objectives	6
2.1 Cardiovascular Diseases	6
2.2 Endothelium and Vasodilatory Endothelial Dysfunction	7
2.3 Relationship between CVD and VED	8
2.4 VED and initiation of Atherosclerosis	10
2.5 Assessment methods of ED and VED	11
2.5.1 Standard Biomarkers	11
2.5.2 Invasive and Non-invasive assessment of VED	11
2.6 Stimulation of Endothelium for Noninvasive Assessment	11
2.7 Impedance plethysmography and VED	12
2.8 Commercially available devices that used to measure VED with physiological parameters	12
2.8.1 PeriFlux System 5000	12
2.8.2 EndoPAT 2000	13
2.8.3 Heart Sentry	14
2.8.4 VENDYS II Endothelix Inc	14
2.9 Drawbacks of the existing devices compared to proposed study	15
2.10 Evidence of the presence of ED in healthy people with CVD risk factors	15

2.11	Specific objectives	16
3	Device Development	18
3.1	Occlusion duration of Reactive Hyperemia	18
3.2	Digital Body Temperature	19
3.3	Peripheral Arterial Tonometry	20
3.4	Photo Plethysmography	23
3.5	Peripheral Bio-Impedance	24
4	Peripheral Bio-impedance	25
4.1	Electrodes selection for PBI measurement	25
4.2	Electrode Configuration for PBI measurement	26
4.3	Inter Electrode Distance	27
4.4	Acquisition device for PBI measurement	28
4.4.1	Keysight E4990A LCR meter	28
4.4.2	EVAL-AD5933EBZ Evaluation Board	30
4.5	Time domain variation of Peripheral Bio-impedance	33
4.5.1	Peripheral Bio-impedance Model for the Forearm	33
4.5.2	Device Integration of PBI	35
4.5.3	Selection of Stimulation Frequencies	36
4.5.4	PBI Measurement Validation	36
5	Device Integration and Data Preprocessing	39
5.1	Device Integration	39
5.2	Data Acquisition	39
5.3	Data Preprocessing	41
6	Device Validation and Preliminary Study	45
6.1	Study Protocol	45
6.2	Preliminary Study	47
6.3	Experimental protocol with Flow Mediated Dilation	48
6.4	Experimental protocol with Custom-made device	49
6.5	Data Normalization	51
6.6	Index Calculation	53
6.7	Preliminary Study Results	54

7	Clinical Study	62
7.1	Blood Sampling	62
7.2	Determination of the Test Subject Category	63
7.2.1	Healthy (Control)	63
7.2.2	Healthy with CVD risk Factors	63
7.2.3	Pre-Diabetes Mellitus	63
7.2.4	Diabetes Mellitus	63
7.2.5	CVD	63
7.3	Anthropometric Data	64
7.4	Laboratory Biomarkers	64
7.5	Data Collection Procedure	64
7.6	Data Preprocessing and Data Normalization	65
7.6.1	Long term variations of Physiological Parameters	65
7.6.2	Short-term variations of Physiological Parameters	66
7.7	Index Calculation	69
7.7.1	Long-term variation Indices	69
7.7.2	Short-term variation Indices	69
7.7.3	Short-term variations of PAT and PPG Parameters	72
7.7.4	Statistical Analysis of Long-term VED Indices	87
7.7.5	Statistical Summary of Long-term VED Indices	95
7.7.6	Statistical Analysis of Short-term VED Indices	96
7.7.7	Statistical Summary of Short-term VED Indices	99
8	Discussion	107
8.1	Custom made device	107
8.2	Data Normalization	108
8.3	Preliminary Study for the Device Validation	108
8.4	Long-term Variation Analysis of the Clinical Study	109
8.5	Short-term Variation Analysis of the Clinical study	110
9	Conclusion	112
9.1	Key Conclusions	112
9.2	Limitations and Future Work	113

References	114
Appendix A Ethical approval documents	127

LIST OF FIGURES

Figure	Description	Page
Figure 1.1	Overview diagram of Linkage of ED towards the development of CVD	2
Figure 1.2	Detection methods of Endothelial Dysfunction	3
Figure 2.1	Anatomical structure of Endothelium adapted from Medical Physiology by Guyton and Hall	8
Figure 2.2	Factors influencing endothelial dysfunction and its consequences	9
Figure 2.3	Progression of the Atherosclerosis in the Arterial Wall adapted from Medical Physiology by Guyton and Hall	10
Figure 2.4	Perifluc 5000 system with PeriCam PSI unit	13
Figure 2.5	Endo-PAT 2000 System	13
Figure 2.6	Heart Sentry Portable Device	14
Figure 2.7	VENDYS II Endothelix, Inc	14
Figure 3.1	Block Diagram of Custom-made Device: (a) Dominant arm (b) Contralateral arm (c) Custom-made device (d) Adult pressure cuff	19
Figure 3.2	TSIC506F TO92 Digital Temperature Sensor	20
Figure 3.3	Size Comparison of Blood Pressure Cuffs: (a) Neonatal (b) Infant (c) Child (d) Adult	21
Figure 3.4	ABPDANT005PGAA5 Analog Pressure Sensor	21
Figure 3.5	PCB designed for PAT signal Data acquisition	22
Figure 3.6	MAX30102 Photoplethysmography Sensor	23
Figure 4.1	Conventional Electrodes: (a) Disk Electrodes (b) Long strip Electrode	25
Figure 4.2	Sanibel BIA Electrodes	26
Figure 4.3	Electrode Configurations: (a) Tetrapolar Configuration (b) Bipolar Configuration	27
Figure 4.4	Keysight E4990A LCR meter	29
Figure 4.5	Relationship between Peripheral Bio-impedance Vs Stimulation Frequency	29
Figure 4.6	EVAL-AD5933EBZ Evaluation board	30
Figure 4.7	EVAL-AD5933EBZ Evaluation board software Graphical User Interface	32
Figure 4.8	EVAL-AD5933EBZ Evaluation board frequency stimulation cycle	32
Figure 4.9	(a) Conduction Pathway of Stimulation Current in the Forearm (b) Peripheral Bio-impedance Equivalent Circuit Model of forearm	34
Figure 4.10	Magnitude Variation of blood impedance (Z_B) and equivalent impedance (Z_{eq}) of the Peripheral Bio-impedance Model for the Forearm	35
Figure 4.11	Bodystat 500 Bio-impedance Measuring Device	37

Figure 4.12	PBI Comparison of Bodystat 500 Vs Custom made Device; (a) PBI variation of BodyStat 500 (b) PBI variation of Custom made device	38
Figure 5.1	The Complete Integrated Devices	40
Figure 5.2	Sensor connections to Test subject	40
Figure 5.3	GUI developed from Processing Software	41
Figure 5.4	Preprocessed DBT Measurements for Occluded Arm and Control Arm	42
Figure 5.5	Preprocessed PAT Measurements for Occluded Arm and Control Arm: (a) Long-term variation (b) Short-term variation	43
Figure 5.6	Preprocessed PPG Measurements for Occluded Arm and Control Arm: (a) Long-term variation (b) Short-term variation	43
Figure 5.7	Preprocessed PBI measurements for Occluded arm and Control on Stimulation Frequencies: (a) 5 kHz (b) 10 kHz (c) 20 kHz (d) 50 kHz	44
Figure 6.1	Experimental Procedure of the Current Research Study	46
Figure 6.2	Toshiba Nemio 35 SSA-550A Diagnostic Ultrasound Machine	49
Figure 6.3	FMD measurements acquired from the Brachial Arteries of both occluded arm (with the pressure cuff) and control arm of the Test Subject	50
Figure 6.4	Real-time FMD measurements observing and freezing the optimum segment to record the data	50
Figure 6.5	Data Acquisition from Custom-made devices	51
Figure 6.6	Normalized Long-term Variations of FMD Parameters: (a) Brachial Artery Diameter Ratio (b) Brachial Artery Flow Rate Ratio	52
Figure 6.7	Normalized Long-term Variations of Custom-made device Parameters: (a) DBT Ratio (b) PAT Ratio (c) PPG Ratio (d) PBI Ratio	53
Figure 6.8	Long-term variations Index Calculation	55
Figure 6.9	Unpaired t-test plots of FMD based VED Indices: (a) FMD-Peak % (b) FMD-Trough % (c) DFI Peak % (Significance Level: * $p<0.05$, *** $p<0.001$)	57
Figure 6.10	Unpaired t-test plots of DBT Long-term Variation VED Indices: (a) Falling Gradient (b) Rising Gradient (c) R/F Ratio (d) AUC (e) Rebound (f) Nadir to Peak (g) Rebound Time (Significance Level: * $p<0.05$)	58
Figure 6.11	Unpaired t-test plots of PAT Long-term Variation VED Indices: (a) Falling Gradient (b) Rising Gradient (c) R/F Ratio (d) AUC (e) Rebound (f) Nadir to Peak (g) Rebound Time (Significance Level: * $p<0.05$)	59
Figure 6.12	Unpaired t-test plots of PPG Long-term Variation VED Indices: (a) Falling Gradient (b) Rising Gradient (c) R/F Ratio (d) AUC (e) Rebound (f) Nadir to Peak (g) Rebound Time (Significance Level: * $p<0.05$, ** $p<0.01$)	60

Figure 6.13	Unpaired t-test plots of PBI Long-term Variation VED Indices: (a) Falling Gradient (b) Rising Gradient (c) R/F Ratio (d) AUC (e) Rebound (f) Nadir to Peak (g) Rebound Time (Significance Level: * $p < 0.05$, ** $p < 0.01$)	61
Figure 7.1	Normalized Long-term Variations of DBT : (a) HRF Vs Healthy (b) PDM Vs Healthy (c) DM Vs Healthy (d) CVD Vs Healthy	66
Figure 7.2	Normalized Long-term Variations of PAT : (a) HRF Vs Healthy (b) PDM Vs Healthy (c) DM Vs Healthy (d) CVD Vs Healthy	67
Figure 7.3	Normalized Long-term Variations of PPG : (a) HRF Vs Healthy (b) PDM Vs Healthy (c) DM Vs Healthy (d) CVD Vs Healthy	67
Figure 7.4	Normalized Long-term Variations of PBI : (a) HRF Vs Healthy (b) PDM Vs Healthy (c) DM Vs Healthy (d) CVD Vs Healthy	68
Figure 7.5	Averaged Pulsatile Short-term Variations at PRH stage (Occluded Arm Vs Control Arm): (a) Short-term Variations of PAT (b) Short-term Variations of PPG	68
Figure 7.6	Short-term Pulsatile variations at the initial minute of the PRH stage: (a) Normalized PAT Short-term Pulsatile variations (b) Normalized PPG Short-term Pulsatile variations	69
Figure 7.7	Parameters and Regions of Pulse for Short term variation Indices	70
Figure 7.8	Normalized Short-term Variations of PAT Reflective Index (RI): (a) HRF Vs Healthy (b) PDM Vs Healthy (c) DM Vs Healthy (d) CVD Vs Healthy	73
Figure 7.9	Normalized Short-term Variations of PAT Natural logarithmic Reflective Index (LnRI): (a) HRF Vs Healthy (b) PDM Vs Healthy (c) DM Vs Healthy (d) CVD Vs Healthy	73
Figure 7.10	Normalized Short-term Variations of PAT Pulse Amplitude Index (Di-Amp): (a) HRF Vs Healthy (b) PDM Vs Healthy (c) DM Vs Healthy (d) CVD Vs Healthy	74
Figure 7.11	Normalized Short-term Variations of PAT Pulse Area Index (Di-Area): (a) HRF Vs Healthy (b) PDM Vs Healthy (c) DM Vs Healthy (d) CVD Vs Healthy	75
Figure 7.12	Normalized Short-term Variations of PAT Stiffness Index (SI): (a) HRF Vs Healthy (b) PDM Vs Healthy (c) DM Vs Healthy (d) CVD Vs Healthy	75
Figure 7.13	Normalized Short-term Variations of PAT Crest Time Index (CT): (a) HRF Vs Healthy (b) PDM Vs Healthy (c) DM Vs Healthy (d) CVD Vs Healthy	76
Figure 7.14	Normalized Short-term Variations of PAT Crest Time Ratio (CTR): (a) HRF Vs Healthy (b) PDM Vs Healthy (c) DM Vs Healthy (d) CVD Vs Healthy	77

Figure 7.15	Normalized Short-term Variations of PAT Delta Time Index (DT): (a) HRF Vs Healthy (b) PDM Vs Healthy (c) DM Vs Healthy (d) CVD Vs Healthy	77
Figure 7.16	Normalized Short-term Variations of PAT Slope Transit Time Index (STT): (a) HRF Vs Healthy (b) PDM Vs Healthy (c) DM Vs Healthy (d) CVD Vs Healthy	78
Figure 7.17	Normalized Short-term Variations of PAT Augmented Index (AI): (a) HRF Vs Healthy (b) PDM Vs Healthy (c) DM Vs Healthy (d) CVD Vs Healthy	78
Figure 7.18	Normalized Short-term Variations of PAT Pulse Width to Amplitude Index (PA): (a) HRF Vs Healthy (b) PDM Vs Healthy (c) DM Vs Healthy (d) CVD Vs Healthy	79
Figure 7.19	Normalized Short-term Variations of PAT Buckberg Sub Endocardial Viability Ratio (BSEVR): (a) HRF Vs Healthy (b) PDM Vs Healthy (c) DM Vs Healthy (d) CVD Vs Healthy	79
Figure 7.20	Normalized Short-term Variations of PPG Reflective Index (RI): (a) HRF Vs Healthy (b) PDM Vs Healthy (c) DM Vs Healthy (d) CVD Vs Healthy	80
Figure 7.21	Normalized Short-term Variations of PPG Natural logarithmic Reflective Index (LnRI): (a) HRF Vs Healthy (b) PDM Vs Healthy (c) DM Vs Healthy (d) CVD Vs Healthy	81
Figure 7.22	Normalized Short-term Variations of PPG Pulse Amplitude Index (Di-Amp): (a) HRF Vs Healthy (b) PDM Vs Healthy (c) DM Vs Healthy (d) CVD Vs Healthy	81
Figure 7.23	Normalized Short-term Variations of PPG Pulse Area Index (Di-Area): (a) HRF Vs Healthy (b) PDM Vs Healthy (c) DM Vs Healthy (d) CVD Vs Healthy	82
Figure 7.24	Normalized Short-term Variations of PPG Stiffness Index (SI): (a) HRF Vs Healthy (b) PDM Vs Healthy (c) DM Vs Healthy (d) CVD Vs Healthy	83
Figure 7.25	Normalized Short-term Variations of PPG Crest Time Index (CT): (a) HRF Vs Healthy (b) PDM Vs Healthy (c) DM Vs Healthy (d) CVD Vs Healthy	83
Figure 7.26	Normalized Short-term Variations of PPG Crest Time Ratio (CTR): (a) HRF Vs Healthy (b) PDM Vs Healthy (c) DM Vs Healthy (d) CVD Vs Healthy	84
Figure 7.27	Normalized Short-term Variations of PPG Delta Time Index (DT): (a) HRF Vs Healthy (b) PDM Vs Healthy (c) DM Vs Healthy (d) CVD Vs Healthy	84

Figure 7.28	Normalized Short-term Variations of PPG Slope Transit Time Index (STT): (a) HRF Vs Healthy (b) PDM Vs Healthy (c) DM Vs Healthy (d) CVD Vs Healthy	85
Figure 7.29	Normalized Short-term Variations of PPG Augmented Index (AI): (a) HRF Vs Healthy (b) PDM Vs Healthy (c) DM Vs Healthy (d) CVD Vs Healthy	86
Figure 7.30	Normalized Short-term Variations of PPG Pulse Width to Amplitude Index (PA): (a) HRF Vs Healthy (b) PDM Vs Healthy (c) DM Vs Healthy (d) CVD Vs Healthy	86
Figure 7.31	Normalized Short-term Variations of PPG Buckberg Sub Endocardial Viability Ratio (BSEVR): (a) HRF Vs Healthy (b) PDM Vs Healthy (c) DM Vs Healthy (d) CVD Vs Healthy	87
Figure 7.32	ANOVA plots of DBT long-term Variation VED Indices: (a) Falling Gradient (b) Rising Gradient (c) R/F Ratio (d) AUC (e) Nadir to Peak (f) Rebound (g) Rebound Time (Significance Level: * $p < 0.05$, ** $p < 0.01$)	88
Figure 7.33	ANOVA plots of PAT long-term Variation VED Indices: (a) Falling Gradient (b) Rising Gradient (c) R/F Ratio (d) AUC (e) Nadir to Peak (f) Rebound (g) Rebound Time (Significance Level: * $p < 0.05$, ** $p < 0.01$, **** $p < 0.0001$)	90
Figure 7.34	ANOVA plots of PPG long-term Variation VED Indices: (a) Falling Gradient (b) Rising Gradient (c) R/F Ratio (d) AUC (e) Nadir to Peak (f) Rebound (g) Rebound Time (Significance Level: * $p < 0.05$, ** $p < 0.01$)	92
Figure 7.35	ANOVA plots of PBI Long-term Variation VED Indices: (a) Falling Gradient (b) Rising Gradient (c) R/F Ratio (d) AUC (e) Nadir to Peak (f) Rebound (g) Rebound Time (Significance Level: * $p < 0.05$, ** $p < 0.01$)	94
Figure 7.36	Heat map of summarized ANOVA results for the long-term VED indices	97
Figure 7.37	ANOVA plots of PAT Short-term Variation VED Indices: (a) Reflective Index (RI) (b) Natural Logarithmic Reflective Index (LnRI) (c) Pulse Amplitude (Di-Amp) (d) Pulse Area (Di-Area) (e) Stiffness Index (SI) (f) Crest Time Index (CT) (Significance Level: * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, **** $p < 0.0001$)	101
Figure 7.38	ANOVA plots of PAT Short-term Variation VED Indices: (g) Crest Time Ratio (CTR) (h) Delta Time Index (DT) (i) Slope Transit Time Index (STT) (j) Augmented Index (AI) (k) Pulse Width to Amplitude Index (PA) (l) Buckberg Sub Endocardial Viability Ratio (BSEVR) (Significance Level: * $p < 0.05$, *** $p < 0.001$, **** $p < 0.0001$)	102

Figure 7.39	ANOVA plots of PPG Short-term Variation VED Indices: (a) Reflective Index (RI) (b) Natural Logarithmic Reflective Index (LnRI) (c) Pulse Amplitude (Di-Amp) (d) Pulse Area (Di-Area) (e) Stiffness Index (SI) (f) Crest Time Index (CT) (Significance Level: * $p < 0.05$, **** $p < 0.0001$)	104
Figure 7.40	ANOVA plots of PPG Short-term Variation VED Indices: (g) Crest Time Ratio (CTR) (h) Delta Time Index (DT) (i) Slope Transit Time Index (STT) (j) Augmented Index (AI) (k) Pulse Width to Amplitude Index (PA) (l) Buckberg Sub Endocardial Viability Ratio (BSEVR) (Significance Level: ** $p < 0.01$, *** $p < 0.001$, **** $p < 0.0001$)	105
Figure 7.41	Heat map of summarized ANOVA results for the short-term VED indices	106

LIST OF TABLES

Table	Description	Page
Table 2.1	Comparison of commercial devices with proposed system	15
Table 4.1	Calibration resistor values for impedance ranges	31
Table 6.1	Anthropometric data of the Participants recruited for the Preliminary study	48
Table 6.2	Preliminary Study Statistical Analysis for VED indices (unpaired t-test)	56
Table 7.1	Anthropometric data of the Clinical study	64
Table 7.2	Biomarker data of the Clinical study	65
Table 7.3	Clinical Study: DBT longterm variation VED indices ANOVA statistical analysis (Healthy Vs HRF)	89
Table 7.4	Clinical Study: DBT longterm variation VED indices ANOVA statistical analysis (Healthy Vs PDM)	89
Table 7.5	Clinical Study: DBT longterm variation VED indices ANOVA statistical analysis (Healthy Vs DM)	89
Table 7.6	Clinical Study: DBT longterm variation VED indices ANOVA statistical analysis (Healthy Vs CVD)	91
Table 7.7	Clinical Study: PAT longterm variation VED indices ANOVA statistical analysis (Healthy Vs HRF)	91
Table 7.8	Clinical Study: PAT longterm variation VED indices ANOVA statistical analysis (Healthy Vs PDM)	91
Table 7.9	Clinical Study: PAT longterm variation VED indices ANOVA statistical analysis (Healthy Vs DM)	93
Table 7.10	Clinical Study: PAT longterm variation VED indices ANOVA statistical analysis (Healthy Vs CVD)	93
Table 7.11	Clinical Study: PPG longterm variation VED indices ANOVA statistical analysis (Healthy Vs HRF)	93
Table 7.12	Clinical Study: PPG longterm variation VED indices ANOVA statistical analysis (Healthy Vs PDM)	95
Table 7.13	Clinical Study: PPG longterm variation VED indices ANOVA statistical analysis (Healthy Vs DM)	95
Table 7.14	Clinical Study: PPG longterm variation VED indices ANOVA statistical analysis (Healthy Vs CVD)	95
Table 7.15	Clinical Study: PBI longterm variation VED indices ANOVA statistical analysis (Healthy Vs HRF)	96

Table 7.16	Clinical Study: PBI longterm variation VED indices ANOVA statistical analysis (Healthy Vs PDM)	96
Table 7.17	Clinical Study: PBI longterm variation VED indices ANOVA statistical analysis (Healthy Vs DM)	96
Table 7.18	Clinical Study: PBI longterm variation VED indices ANOVA statistical analysis (Healthy Vs CVD)	97
Table 7.19	Clinical Study Statistical Analysis (ANOVA) Healthy Vs HRF for the PAT VED indices of Short-term variations	98
Table 7.20	Clinical Study Statistical Analysis (ANOVA) Healthy Vs PDM for the PAT VED indices of Short-term variations	98
Table 7.21	Clinical Study Statistical Analysis (ANOVA) Healthy Vs DM for the PAT VED indices of Short-term variations	99
Table 7.22	Clinical Study Statistical Analysis (ANOVA) Healthy Vs CVD for the PAT VED indices of Short-term variations	99
Table 7.23	Clinical Study Statistical Analysis (ANOVA) Healthy Vs HRF for the PPG VED indices of Short-term variations	100
Table 7.24	Clinical Study Statistical Analysis (ANOVA) Healthy Vs PDM for the PPG VED indices of Short-term variations	100
Table 7.25	Clinical Study Statistical Analysis (ANOVA) Healthy Vs DM for the PPG VED indices of Short-term variations	103
Table 7.26	Clinical Study Statistical Analysis (ANOVA) Healthy Vs CVD for the PPG VED indices of Short-term variations	103

LIST OF APPENDICES

Appendix	Description	Page
Appendix -A	Ethical approval documents	127